跳至主要内容
临床试验/NCT00186394
NCT00186394已完成2 期

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma

Stanford University2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2000年4月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
35
试验地点
2
主要终点
Safety

研究概览

简要总结

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

详细描述

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 61 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Morphologically confirmed relapsed non-Hodgkin's lymphoma
  • Age: >18 and <61 years of age
  • Signed informed consent

排除标准

  • Hepatic dysfunction defined by serum transaminases >2.5X normal values
  • Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min
  • Diseases other than non-Hodgkin's lymphoma
  • Prior bone marrow transplant procedure
  • Severe psychological or medical illness

结局指标

主要结局

Safety

Toxicity

Efficacy

次要结局

  • Incidence of acute and chronic GVHD

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

High Dose Chemotherapy and Allogeneic Hematopoietic... | 临床试验